Decorin

Mechanism of Action

• Binds TGF-beta1/2/3 with high affinity via leucine-rich repeat domain, sequestering it in ECM and preventing SMAD2/3 activation (anti-fibrotic)
• Directly binds EGFR extracellular domain, inducing receptor internalization and sustained ERK1/2 activation followed by p21 upregulation and growth arrest
• VEGFR2 antagonism: decorin core protein competes with VEGF-A for receptor occupancy, reducing endothelial proliferation and tumor angiogenesis
• Acts as a signaling platform: decorin engagement of EGFR triggers autophagy via BECN1/LC3 axis, suppressing tumor cell survival
• Regulates collagen fibrillogenesis: binds collagen I/II/III to control fibril diameter and tensile strength in connective tissue

Research Findings

• Decorin knockout mice develop fragile skin with abnormal collagen fibril ultrastructure (thicker, irregular fibrils)
• Systemic decorin protein reduced TGF-beta-driven fibrosis in kidney, liver, and lung disease models
• Tumor-targeted decorin gene delivery (Ad-DCN) suppressed tumor growth and angiogenesis in multiple xenograft models
• Decorin expression inversely correlates with tumor grade in breast, colon, and bladder cancers
• Decorin induces mitophagy in breast carcinoma cells, selectively targeting cancer cell bioenergetics
• Clinical trials exploring decorin protein or mimetics for diabetic nephropathy and pulmonary fibrosis ongoing

Research Protocols

• Recombinant decorin core protein: 10-300 nM in cell-based assays for TGF-beta neutralization or RTK inhibition
• In vivo fibrosis models: 4-16 mg/kg IV or SC 3x/week of recombinant decorin in UUO kidney or bleomycin lung models
• Ad-DCN adenovirus gene delivery: 10^9-10^11 particles IV or intratumoral for cancer models
• Decorin-mimetic peptides (LRR domain fragments): 50-500 nM in endothelial angiogenesis assays

Interactions

• TGF-beta: primary ligand; decorin sequesters and neutralizes all three TGF-beta isoforms
• Myostatin (GDF-8): decorin binds and inhibits myostatin signaling; basis for muscle hypertrophy research
• EGFR and VEGFR2 inhibitors: potential additive anti-tumor effects when combined with decorin administration

Safety Profile

Recombinant decorin well tolerated in preclinical models at anti-fibrotic and anti-tumor doses. No approved therapeutic. Decorin is the molecular target of myostatin inhibition interest; decorin mimetic peptides being developed for fibrosis and cancer with no reported significant adverse effects in animal studies.

Legal & Regulatory

Research/investigational; no approved therapeutic product